1. Home
  2. MRKR

as 11-14-2024 11:35am EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Founded: N/A Country:
United States
United States
Employees: N/A City: HOUSTON
Market Cap: 35.8M IPO Year: N/A
Target Price: $19.00 AVG Volume (30 days): 35.3K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.17 EPS Growth: N/A
52 Week Low/High: $2.44 - $6.16 Next Earning Date: 11-22-2024
Revenue: $3,727,435 Revenue Growth: -0.75%
Revenue Growth (this year): 35.94% Revenue Growth (next year): N/A

MRKR Daily Stock ML Predictions

Share on Social Networks: